1 |
Plant derived (Sparassis crispa, Phellinus linteus, Platycodon grandiflorum, Cordyceps millitaris, and Angelica gigas Nakai) |
In vitro
|
DC maturation; Translocation of NF-κB subunits to the nucleus |
(94) |
2 |
Mushroom and barley |
In vitro
|
PBMC proliferation; IL-12 and IL-10 production |
(95) |
3 |
Cellulose |
In vitro
|
No immunomodulation |
(95) |
4 |
Spent Brewers’ Yeast (Saccharomyces cerevisiae) |
In vivo - rats and human clinical trials |
Phagocytosis, oxidative burst, production of cytokines and chemokines in dendritic cells and macrophages; interleukin-1β (IL-1β) |
(96) |
5 |
Curdlan (Alcaligenes faecalis) |
In vitro
|
Activation of MAPKs and NF-κB Pathways; M1 Phenotype Polarization |
(97) |
6 |
Euglena gracilis |
In vitro and animal studies |
Transactivation of NF-κB; expression of proinflammatory mediators (TNF-α, IL-6, COX2, and iNOS); production of high level of NO |
(98) |
7 |
Synthetic Beta-glucan (βglu6) |
In vitro
|
Secretion of large levels of cytokines and chemokines, including CD54, IL-1α, IL-1β, IL-16, IL-17, IL-23, IFN-γ, CCL1, CCL3, CCL4, CCL12, CXCL10, tissue inhibitor of metalloproteinase-1 (TIMP-1) and G-CSF in murine macrophages as well as IL-6, CCL2, CCL3, CCL5, CXCL1 and macrophage migration inhibitory factor (MIF) |
(99) |
8 |
Mushroom Pleurotus ostreatus |
Human clinical trials |
Increased number of circulating natural killer cells as well as a preventive effect on the reduction of natural killer cell activity |
(100) |
9 |
PGG Glucan Saccharomyces cerevisiae |
In vitro
|
Enhanced neutrophil anti-microbial functions |
(101) |
10 |
Fungus Sclerotinia sclerotiorum IFO 939 |
In vitro
|
Enhanced Phagocytic activity and interleukin-1 (IL-1) production |
(102) |
11 |
Shiitake medicinal mushroom, Lentinus edodes (Berk.) singer mycelium |
Human clinical trial |
Increase in the number of circulating B-cells |
(103) |
12 |
Algae |
In vitro
|
Increase in phagocytic activity; stimulation of IL-2 secretion |
(104) |
13 |
Agrobacterium-derived |
14 |
Oats |
15 |
Pustulan (β-(1,6)-glucan), lichenan (β-(1,3)-(1,4)- glucan), xyloglucan (β-(1,4)- glucan), and pullulan (α-(1,4)- (1,6)-glucan) |
In vitro
|
Strong cytokine production |
(105) |
16 |
Aureobasidium pullulans |
In vitro, animal models and human clinical studies |
Increase in production of interleukin-8 (IL-8) or soluble Fas (sFas); Decrease in IL-1beta, IL-2, IL-6, IL-12 (p70+40), interferongamma (IFN-gamma), tumor necrosis factoralpha (TNF-alpha) or soluble Fas ligand (sFasL); Decrease of CRP, Ferritin and DDimer; Increase in NK cells and T cells; Activation of Dendritic cells; Activation of MAPKs and NF-κB Pathways; Stimulation of Macrophages |
(38, 39, 41, 42, 49–51) |